Phospho-NFATC1 (S294) Antibody

What is Phospho-NFATC1 (S294) and why is it significant in research?

Phospho-NFATC1 (S294) refers to the Nuclear Factor of Activated T-cells, cytoplasmic 1 (NFATC1) protein when specifically phosphorylated at the serine 294 residue. NFATC1 plays a crucial role in multiple cellular processes, particularly in the immune system and skeletal development. The phosphorylation state of NFATC1 at S294 is critical for regulating its cellular localization and activity. When phosphorylated, NFATC1 is typically exported from the nucleus, while dephosphorylation by calcineurin promotes its nuclear import . This phosphorylation-dependent regulation is fundamental to NFATC1's function as a transcription factor. Research has established that NFATC1 is essential for osteoclast differentiation in vivo, making it a significant target for bone disease therapies . Additionally, NFATC1 plays a role in inhibiting osteoblast differentiation and function, further emphasizing its importance in bone homeostasis research .

What applications are Phospho-NFATC1 (S294) antibodies suitable for?

Phospho-NFATC1 (S294) antibodies are specifically designed to detect NFATC1 only when phosphorylated at the S294 residue. These antibodies are suitable for multiple research applications, primarily Immunohistochemistry (IHC), Immunofluorescence (IF), and Enzyme-Linked Immunosorbent Assay (ELISA) . The recommended dilution ranges vary by application: for Western Blotting, a dilution range of 1:500-2000 is suggested; for IHC, 1:100-1:300; for ELISA, 1:10000; and for IF, 1:50-200 . These applications allow researchers to study the phosphorylation state of NFATC1 in various experimental contexts, including tissue sections, cultured cells, and protein extracts. It's important to note that these antibodies are strictly for research use only and must not be used in diagnostic or therapeutic applications . Researchers should optimize the dilution for their specific experimental conditions to achieve optimal signal-to-noise ratios.

How does phosphorylation at S294 affect NFATC1 function?

Phosphorylation at S294 of NFATC1 plays a critical role in regulating its subcellular localization and activity. When NFATC1 is phosphorylated by NFATC-kinase and GSK3B at sites including S294, it undergoes nuclear export, which inhibits its transcriptional activity . Conversely, dephosphorylation by calcineurin promotes nuclear import, enabling NFATC1 to function as a transcription factor. This phosphorylation-dephosphorylation cycle is essential for the proper functioning of NFATC1 in various cellular processes. Additionally, phosphorylation by protein kinase A (PKA) and DYRK2 negatively regulates nuclear accumulation of NFATC1 and promotes subsequent phosphorylation by GSK3B or casein kinase 1 . These complex phosphorylation patterns, including the S294 site, are integral to NFATC1's role in regulating gene expression in various cell types, including T-cells and bone cells. In osteoclasts, for instance, the phosphorylation state of NFATC1 influences its ability to drive differentiation through an autoregulatory mechanism involving its own promoter .

What are the technical specifications of commercially available Phospho-NFATC1 (S294) antibodies?

Commercially available Phospho-NFATC1 (S294) antibodies, such as the rabbit polyclonal antibody from St. John's Labs (STJ91118), have specific technical characteristics that researchers should consider. These antibodies are typically generated in rabbits as polyclonal IgG antibodies that recognize the region surrounding the S294 phosphorylation site (amino acids 261-310) . They are usually supplied as liquid formulations in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide at a concentration of 1 mg/mL .

The antibodies are affinity-purified from rabbit antiserum using epitope-specific immunogens to ensure specificity for the phosphorylated form of NFATC1. They specifically detect endogenous levels of NFATC1 protein only when phosphorylated at S294 . These antibodies typically show reactivity with human and mouse samples, making them versatile for various research models . Storage recommendations include keeping the antibody at -20°C for up to one year from the date of receipt, while avoiding repeated freeze-thaw cycles that could compromise antibody integrity and performance .

How do different kinases and phosphatases regulate the phosphorylation state of NFATC1 at S294?

The phosphorylation state of NFATC1 at S294 is regulated by a complex interplay of kinases and phosphatases that modulate NFATC1's subcellular localization and transcriptional activity. Several kinases have been identified that phosphorylate NFATC1, including NFATC-kinase, GSK3B, PKA, and DYRK2 . These kinases phosphorylate NFATC1 at multiple sites, including S294, promoting its nuclear export and inhibiting its transcriptional activity. Conversely, the calcium-dependent phosphatase calcineurin dephosphorylates NFATC1, enabling its nuclear import and activation .

The sequential phosphorylation of NFATC1 adds another layer of complexity to its regulation. For instance, phosphorylation by PKA and DYRK2 not only affects nuclear accumulation directly but also creates priming sites that facilitate subsequent phosphorylation by GSK3B or casein kinase 1 . This hierarchical phosphorylation pattern suggests that S294 phosphorylation should be studied in the context of other phosphorylation events. Researchers investigating S294 phosphorylation should consider using kinase and phosphatase inhibitors such as cyclosporin (a calcineurin inhibitor) to manipulate NFATC1's phosphorylation state . When using Phospho-NFATC1 (S294) antibodies, it's crucial to include appropriate controls to account for these regulatory mechanisms, such as samples treated with phosphatase inhibitors to preserve phosphorylation states during cell lysis and protein extraction.

What are the methodological challenges in distinguishing between direct and indirect effects on NFATC1 S294 phosphorylation?

Distinguishing between direct and indirect effects on NFATC1 S294 phosphorylation presents significant methodological challenges in research. One major challenge arises from the complex signaling networks that converge on NFATC1 regulation. For example, studies have shown that connexin 37 (Cx37) affects ERK activation, which in turn influences the phosphorylation of transcription factors at specific sites, including S294 . This illustrates how changes in S294 phosphorylation may result from upstream signaling events rather than direct kinase activity on NFATC1.

How does the phosphorylation of NFATC1 at S294 impact its interaction with other transcription factors and chromatin modifiers?

The phosphorylation state of NFATC1 at S294 significantly influences its interactions with other transcription factors and chromatin modifiers, which ultimately affects gene expression patterns. Research has demonstrated that NFATc1 can interact with histone deacetylases (HDACs), particularly HDAC3, to repress gene expression . In osteoblasts, NFATc1 has been shown to sustain the binding of HDAC3 to the proximal region of the osteocalcin promoter, resulting in hypoacetylation of histones H3 and H4 . This interaction is modulated by the phosphorylation state of NFATc1, as inhibition of NFATc1 nuclear translocation (which is regulated by phosphorylation) prevents HDAC3 from associating with the osteocalcin promoter .

Furthermore, NFATc1 affects TCF/LEF transcriptional activity, which is involved in Wnt signaling and osteoblast differentiation . The phosphorylation status of NFATc1, including at S294, likely influences these interactions, as nuclear localization of NFATc1 is prerequisite for these effects. Studies have shown that while NFATc1 activation reduces TCF/LEF transcriptional activity, it does not alter the total protein levels of TCF/LEF co-activators (β-catenin) or co-repressors (HDACs1-4) . Instead, NFATc1 appears to modulate the functional interactions between these factors and their target promoters. When investigating the role of S294 phosphorylation in these interactions, researchers should employ chromatin immunoprecipitation (ChIP) assays to assess the occupancy of NFATc1 and associated factors at target promoters under different phosphorylation conditions. Co-immunoprecipitation studies with phospho-specific antibodies can also reveal how S294 phosphorylation affects protein complex formation.

What controls should be included when using Phospho-NFATC1 (S294) antibodies in experiments?

When using Phospho-NFATC1 (S294) antibodies in experiments, incorporating appropriate controls is essential for validating results and ensuring specificity. First, a negative control using samples where NFATC1 is dephosphorylated should be included. This can be achieved by treating samples with phosphatases or using cells treated with calcineurin activators, which promote NFATC1 dephosphorylation . Conversely, a positive control can be generated by treating cells with agents that activate kinases known to phosphorylate NFATC1 at S294, such as GSK3B activators .

For genetic validation, researchers should consider using NFATC1 knockout or knockdown samples to confirm antibody specificity. Additionally, peptide competition assays, where the antibody is pre-incubated with the phosphopeptide used as the immunogen (covering amino acids 261-310 with phosphorylated S294), can verify signal specificity . When performing Western blot analysis, a non-phospho-specific NFATC1 antibody should be run in parallel to distinguish between changes in phosphorylation status versus changes in total NFATC1 protein levels. For immunohistochemistry or immunofluorescence applications, researchers should include secondary antibody-only controls to assess non-specific binding. Furthermore, when studying the effects of compounds on NFATC1 phosphorylation, appropriate vehicle controls must be included. Finally, loading controls for Western blots (e.g., β-actin, GAPDH) and cellular compartment markers for subcellular localization studies are necessary to ensure accurate interpretation of results.

How should researchers optimize protocols for detecting phosphorylated NFATC1 at S294 in different sample types?

Optimizing protocols for detecting phosphorylated NFATC1 at S294 requires careful consideration of sample type, preservation of phosphorylation state, and appropriate detection methods. For cell culture samples, rapid lysis in the presence of phosphatase inhibitors is crucial to prevent artificial dephosphorylation. Researchers should use ice-cold lysis buffers containing phosphatase inhibitor cocktails and perform all extraction steps at 4°C. For tissue samples, snap-freezing immediately after collection or fixation with phosphorylation-preserving fixatives is recommended. When using formalin-fixed paraffin-embedded (FFPE) tissues, antigen retrieval conditions must be carefully optimized, as harsh conditions may destroy the phospho-epitope.

For Western blotting applications, researchers should optimize transfer conditions based on NFATC1's molecular weight (approximately 140 kDa when phosphorylated) . Longer transfer times or lower methanol concentrations in transfer buffers may improve the transfer of this larger protein. The recommended dilution range for Western blotting is 1:500-2000, but researchers should perform titration experiments to determine the optimal concentration for their specific samples .

For immunohistochemistry (dilution range 1:100-1:300) and immunofluorescence (dilution range 1:50-200), blocking conditions should be optimized to minimize background while preserving specific staining . For ELISA applications (recommended dilution 1:10000), sandwich ELISA formats with capture antibodies against total NFATC1 and detection using the phospho-specific antibody may offer increased sensitivity and specificity . In all applications, researchers should consider the nature of their samples (human or mouse) as the antibody has been validated for both species . For each new sample type or experimental condition, optimization experiments comparing different fixation methods, extraction protocols, antibody concentrations, and incubation times are strongly recommended.

What are the best practices for preserving phosphorylation states during sample preparation?

Preserving phosphorylation states during sample preparation is critical for accurate analysis of NFATC1 S294 phosphorylation. Phosphorylation is a labile post-translational modification that can be rapidly lost due to endogenous phosphatase activity. To maintain phosphorylation integrity, researchers should implement several key practices. First, all buffers and solutions should contain comprehensive phosphatase inhibitor cocktails that target multiple classes of phosphatases. These typically include inhibitors of serine/threonine phosphatases (such as okadaic acid, calyculin A), tyrosine phosphatases (sodium orthovanadate), and acid phosphatases (sodium fluoride, β-glycerophosphate).

Sample handling should minimize the time between tissue/cell collection and processing, with all steps performed at 4°C to reduce phosphatase activity. For tissue samples, snap-freezing in liquid nitrogen immediately after collection is recommended, followed by homogenization in cold lysis buffer containing phosphatase inhibitors. When working with cultured cells, direct lysis in the culture dish is preferable to minimize processing time. The lysis buffer should be added directly to cells after quickly removing culture medium and rinsing with ice-cold PBS containing phosphatase inhibitors.

For Western blotting applications, samples should be denatured immediately after lysis by adding SDS sample buffer and heating, which inactivates phosphatases. When running SDS-PAGE, researchers should include phosphorylation standards or control samples with known phosphorylation states. For immunohistochemistry and immunofluorescence, tissues should be fixed rapidly with phosphorylation-preserving fixatives such as formaldehyde supplemented with phosphatase inhibitors. Lengthy fixation should be avoided as it may cause epitope masking or dephosphorylation. Throughout all experimental procedures, researchers should maintain sample integrity by avoiding multiple freeze-thaw cycles, which can activate phosphatases and degrade phosphorylated epitopes .

How can researchers validate the specificity of Phospho-NFATC1 (S294) antibody detection?

Validating the specificity of Phospho-NFATC1 (S294) antibody detection is essential for ensuring reliable research outcomes. A comprehensive validation strategy should incorporate multiple complementary approaches. First, researchers should conduct peptide competition assays using the specific phosphopeptide that served as the immunogen (amino acids 261-310 of human NFAT2 with phosphorylated S294) . Pre-incubation of the antibody with this phosphopeptide should abolish specific staining, while incubation with the corresponding non-phosphorylated peptide should not affect antibody binding.

Genetic validation through NFATC1 knockdown or knockout models provides another critical specificity control. Signal from the phospho-specific antibody should be greatly reduced or eliminated in samples lacking NFATC1 expression. Additionally, researchers can employ site-directed mutagenesis to create S294A (phospho-deficient) mutants of NFATC1. When expressed in cells, these mutants should not be recognized by the phospho-specific antibody.

Pharmacological validation using compounds that modulate NFATC1 phosphorylation can further confirm antibody specificity. Treatment with calcineurin inhibitors like cyclosporin A should increase NFATC1 phosphorylation and enhance antibody signal, while treatment with kinase inhibitors targeting GSK3B should reduce phosphorylation and decrease signal . Parallel detection with multiple antibodies recognizing different regions of NFATC1 or different phosphorylation sites can provide additional validation. Finally, correlation of antibody signal with functional outcomes known to be associated with NFATC1 phosphorylation, such as nuclear export or transcriptional repression of target genes like osteocalcin, can provide functional validation of specificity .

How can Phospho-NFATC1 (S294) antibodies be used to study NFATC1's role in osteoclast differentiation?

Phospho-NFATC1 (S294) antibodies can be instrumental in studying NFATC1's critical role in osteoclast differentiation. Research has established that NFATc1 is essential for osteoclast differentiation in vivo, making it a key target for bone disease therapies . To investigate this role, researchers can employ these antibodies in multiple experimental approaches. Immunohistochemistry using Phospho-NFATC1 (S294) antibodies (at dilutions of 1:100-1:300) can visualize the spatial and temporal patterns of NFATC1 phosphorylation during osteoclast differentiation in bone tissue sections . This approach can reveal how phosphorylation states change during the differentiation process and in response to various stimuli.

Western blotting with the antibody (at dilutions of 1:500-2000) can quantify changes in S294 phosphorylation during osteoclast differentiation time courses . This technique should be complemented with blotting for total NFATC1 to distinguish between changes in phosphorylation versus total protein expression, especially considering NFATC1's autoamplification mechanism . Immunofluorescence (at dilutions of 1:50-200) can be used to track the subcellular localization of phosphorylated NFATC1 during differentiation, as phosphorylation promotes nuclear export while dephosphorylation facilitates nuclear import .

To study the functional significance of S294 phosphorylation in osteoclastogenesis, researchers can manipulate this phosphorylation using genetic approaches (phospho-mimetic or phospho-deficient mutations) or pharmacological approaches (kinase inhibitors, phosphatase inhibitors) and then assess the impact on differentiation markers and osteoclast function. The antibody can then be used to confirm the efficacy of these manipulations. Chromatin immunoprecipitation (ChIP) assays combined with the use of Phospho-NFATC1 (S294) antibodies can reveal how phosphorylation affects NFATC1's binding to its own promoter region, which is critical for the autoamplification mechanism that underlies its essential role in osteoclast differentiation .

What techniques can be used to study the relationship between NFATC1 phosphorylation and histone deacetylation?

The relationship between NFATC1 phosphorylation and histone deacetylation represents a critical aspect of NFATC1's function as a transcriptional regulator. Research has shown that NFATc1 can act as a transcriptional co-repressor through interactions with histone deacetylases (HDACs), particularly HDAC3 . To study this relationship, researchers can employ several advanced techniques. Chromatin Immunoprecipitation (ChIP) assays using Phospho-NFATC1 (S294) antibodies can determine whether the phosphorylation state of NFATC1 affects its recruitment to specific promoter regions. Sequential ChIP (re-ChIP) can be used to determine whether phosphorylated NFATC1 and HDACs (particularly HDAC3) co-occupy the same genomic regions, such as the osteocalcin promoter .

Co-immunoprecipitation (Co-IP) experiments with Phospho-NFATC1 (S294) antibodies can assess whether phosphorylation affects NFATC1's ability to physically interact with HDACs. Researchers should compare these interactions using wild-type NFATC1 versus phospho-mimetic (S294D) or phospho-deficient (S294A) mutants. HDAC activity assays in cellular contexts with different NFATC1 phosphorylation states can determine the functional consequence of these interactions. Studies have shown that overexpression of NFATc1 blocks the decrease in total HDAC activity during osteoblast differentiation .

Chromatin accessibility assays such as ATAC-seq or DNase-seq can reveal how NFATC1 phosphorylation affects chromatin structure at target genes. These can be complemented with ChIP-seq for histone modifications (particularly acetylation marks on histones H3 and H4) to create genome-wide maps of how NFATC1 phosphorylation influences the epigenetic landscape . Reporter gene assays using promoters of NFATC1 target genes (such as osteocalcin) can assess how manipulations of NFATC1 phosphorylation and HDAC activity affect transcriptional output . Finally, proximity ligation assays (PLA) can visualize in situ interactions between phosphorylated NFATC1 and HDACs in their native cellular context, providing spatial information about where and when these interactions occur.

How can researchers investigate the cross-talk between NFATC1 S294 phosphorylation and other signaling pathways?

Investigating the cross-talk between NFATC1 S294 phosphorylation and other signaling pathways requires sophisticated experimental approaches that can capture the dynamic and complex nature of cellular signaling networks. One key pathway interaction to examine is between NFATC1 and the ERK signaling pathway, as research has shown connections between ERK activation and phosphorylation events at S294 in certain contexts . To study these interactions, researchers can use pharmacological inhibitors targeting specific kinases (such as U0126 for MEK/ERK inhibition) and then assess the impact on NFATC1 S294 phosphorylation using the Phospho-NFATC1 (S294) antibody in Western blotting or immunofluorescence applications .

Researchers can also employ reverse approaches, manipulating NFATC1 activity through overexpression of constitutively active or dominant-negative forms and then examining the effect on other signaling pathways using phospho-specific antibodies for key signaling molecules. Multi-color immunofluorescence or flow cytometry with Phospho-NFATC1 (S294) antibody and antibodies against phosphorylated components of other pathways can reveal correlations at the single-cell level. Temporal analysis is crucial for understanding signaling cross-talk, so time-course experiments following stimulation with various agonists should be conducted to determine the sequence of phosphorylation events.

Phosphoproteomics approaches can provide a comprehensive view of how manipulating NFATC1 phosphorylation affects the global phosphorylation landscape in cells. This can reveal unexpected connections to other signaling networks. To understand functional consequences, researchers can assess how NFATC1 S294 phosphorylation affects the activation of transcriptional reporters for other pathways, such as TCF/LEF reporters for Wnt signaling . Finally, computational modeling of signaling networks incorporating experimental data can help predict and test hypotheses about pathway cross-talk. These models can generate testable predictions about how perturbations in one pathway might affect NFATC1 phosphorylation and vice versa.

What experimental approaches can determine how S294 phosphorylation affects NFATC1's binding to target gene promoters?

Determining how S294 phosphorylation affects NFATC1's binding to target gene promoters requires a multi-faceted experimental approach that integrates molecular, cellular, and genomic techniques. Chromatin Immunoprecipitation (ChIP) using Phospho-NFATC1 (S294) antibodies is a fundamental technique for this investigation. By comparing ChIP results with phospho-specific versus total NFATC1 antibodies, researchers can determine whether phosphorylation at S294 enhances or diminishes binding to specific promoter regions. This can be expanded to ChIP-seq for genome-wide analysis of how phosphorylation affects the entire NFATC1 binding landscape.

Electrophoretic Mobility Shift Assays (EMSAs) using recombinant NFATC1 proteins with different phosphorylation states (either purified from cells or generated through in vitro kinase reactions) can assess how S294 phosphorylation directly affects DNA binding affinity in a controlled system. Supershift assays with the Phospho-NFATC1 (S294) antibody can confirm the presence of phosphorylated NFATC1 in DNA-protein complexes. Luciferase reporter assays using promoters of NFATC1 target genes (such as osteocalcin) can determine the functional consequence of S294 phosphorylation on transcriptional activity . These should be performed with wild-type NFATC1 compared to phospho-mimetic (S294D) or phospho-deficient (S294A) mutants.

ChIP-reChIP experiments can reveal how S294 phosphorylation affects NFATC1's co-occupancy with other transcription factors or chromatin modifiers at target promoters. For instance, these experiments could examine co-occupancy with HDAC3, which has been shown to interact with NFATC1 at the osteocalcin promoter . DNA binding site selection assays (SELEX) with phosphorylated versus non-phosphorylated NFATC1 can determine whether phosphorylation alters sequence preference. Finally, in vivo footprinting assays can reveal how S294 phosphorylation affects chromatin accessibility at NFATC1 binding sites in the native cellular context. Together, these approaches provide a comprehensive understanding of how this specific phosphorylation event modulates NFATC1's interactions with its target genes.